HURA · Healthcare
Tuhura Biosciences Inc
8/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
10
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$127M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About TUHURA BIOSCIENCES INC
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific…
Who's behind the signal
Every informed buyer we can see on HURA, across all three feeds.
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 1 on record
Disclosures from 2024-10-18 to 2024-10-18
The newest disclosure we hold for this stock is 2024-10-18.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2024-10-18 | Laurel M. Lee · R-FL | House | Sold | $100,001 - $250,000 |
Not a model pick — but on our radar.
TUHURA BIOSCIENCES INC isn't in the top-10 model right now, but 2 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
2
Investors
1
New positions
0
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−30%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to TUHURA BIOSCIENCES INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell TUHURA BIOSCIENCES INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订